Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology

blog.png
August 17, 2018 Facilitating Drug Discovery with 3D In Vitro Oncology Models Around 95% of new anticancer drugs eventually fail in clinical trials, despite promising results when tested on 2D in vitro preclinical models. New models that better mimic tumor biology in vivo can facilitate more efficient and translatable drug discovery research. LEARN MORE
July 26, 2018 IDO to I DON’T – IDO1 Inhibitor Development News As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that ... LEARN MORE
July 5, 2018 Personalized Cancer Immunotherapy Precision medicine and immunotherapy are currently two of the hottest areas of cancer research. How can immuno-oncology ... LEARN MORE
July 3, 2018 Custom Murine Tumor Homografts for Efficacy Assessment Murine tumor homografts provide an immunotherapeutic efficacy testing platform with the strengths of GEMM paired with ... LEARN MORE
June 28, 2018 Assessing Combination Therapies in Syngeneic Tumor Models Combination immunotherapy could enhance the clinical benefits of monotherapies and overcome patient lack of response to ... LEARN MORE
June 26, 2018 Why to Use Isotype Control Antibodies Good experimental design is key to accurate and precise drug development. Isotype control antibodies, designed and ... LEARN MORE
June 21, 2018 Immunocompetent Murine Models for Immunotherapy Assessment Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model platforms are available for the evaluation of cross reactive and surrogate agents. Here we look at syngeneics, GEMM, and murine tumor homograft models and how to choose the best model for your immuno-oncology study. LEARN MORE
June 12, 2018 Leveraging PDX Models for In Vitro and Ex Vivo Assays Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ... LEARN MORE
June 5, 2018 PDX and Personalized Medicine We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to ... LEARN MORE
May 31, 2018 Predictive Immuno-Oncology Studies with Humanized PDX Patient-derived xenograft (PDX) models are typically immunodeficient and inappropriate for most immuno-oncology (I/O) ... LEARN MORE
May 29, 2018 Webinar FAQ: PDX Models in Drug Discovery Assays Patient-derived xenografts (PDX) are the most predictive and translational preclinical xenograft models available for oncology research. Novel platforms are expanding their use into in vitro and ex vivo drug discovery assays, opening new applications for PDX throughout the preclinical drug discovery pipeline. LEARN MORE
May 24, 2018 Webinar FAQ: Humanized PDX Models in Immuno-Oncology Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ... LEARN MORE
May 22, 2018 Immuno-Oncology and the Microbiome at AACR 2018 CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, ... LEARN MORE
May 17, 2018 Genetically Engineered or Syngeneic Mouse Models? Mouse models are a mainstay of preclinical cancer research, and immunocompetent model use is rising with continued ... LEARN MORE
May 15, 2018 Murine Homograft Tumor Models at AACR 2018 We presented a wide range of immuno-oncology model data at AACR 2018, with three of our thirteen posters covering our ... LEARN MORE